3 results about "Recombinant Chimeric Proteins" patented technology

This invention relates to the application of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 in the preparation of a kit for detecting avian adenovirus serotype 4 antibodies. The amino acid sequence of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 is shown in SEQ ID NO.1. This invention utilizes the multi-epitope recombinant chimeric protein rcF2 to establish an indirect ELISA detection method and kit for detecting avian adenovirus serotype 4. This recombinant chimeric protein can be recognized by avian adenovirus serotype 4 positive sera, and the detection sensitivity of positive sera samples can reach 1:16000. It shows no cross-reactivity with antibodies against other pathogens, indicating that the ELISA detection method based on this multi-epitope recombinant chimeric protein rcF2 is simple to operate, enhances detection sensitivity, and has good specificity and repeatability.

The invention relates to a process for producing an antimalarial vaccine composition containing the recombinant chimeric protein SEQ ID NO: 2, which comprises a conserved region I, targeted by neutralising antibodies, linked to an immunodominant region containing repeats of central amino acids from the different alleles (VK210, P. vivax-like and VK247) of the circumsporozoite protein (PvCSP), predominant on the surface of sporozoites, the infective form of Plasmodium vivax, followed by the C-terminal domain region, target of T lymphocytes, of the PvCSP protein. It also relates to the vaccine composition produced by said process, which is directed at malaria caused by Plasmodium vivax and presents high immunogenicity and protection, with efficacy superior to that of the compositions presented in the prior art. The process revealed in this technology allows the production of a high-purity API (100% by RP-HPLC and 98.8% by SE-HPLC) with a high yield (5,082.5 mg from 3L of purified supernatant).

The invention discloses a recombinant chimeric protein and application thereof in preparation of a goatpox virus virus vaccine, and belongs to the technical field of biological medicines. The amino acid sequence of the recombinant chimeric protein is as shown in SEQ ID NO: 1, and the recombinant chimeric protein is formed by connecting four common B cell antigen epitopes of LSDV and GTPV in series through flexible connecting peptides. The protein can be subjected to efficient soluble expression through a prokaryotic expression system, can be specifically recognized by LSDV infected serum and GTPV immune serum, and has good immunogenicity. Animal experiments show that a subunit vaccine prepared by taking the protein as an immunogen can induce a mouse to generate a neutralizing antibody aiming at LSDV and GTPV, and after challenge, visceral viral load is remarkably reduced, tissue pathological damage is relieved, and effective immune protection is provided. As a safe and efficient subunit vaccine antigen, the recombinant chimeric protein provided by the invention has a wide application prospect in the aspect of preparing broad-spectrum goat pox virus virus vaccines.